Phillip Pang - 22 Feb 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Medical Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Issuer symbol: VIR
Transactions as of: 22 Feb 2023
Net transactions value: -$74,750
Form type: 4
Filing time: 24 Feb 2023, 19:29:47 UTC
Previous filing: 21 Feb 2023
Next filing: 28 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+60,000	+42%	$0.000000	201,198	22 Feb 2023	Direct	F1
transaction	VIR	Common Stock	Sale	$74,750	-2,878	-1.4%	$25.97	198,320	23 Feb 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+70,000		$0.000000	70,000	22 Feb 2023	Common Stock	70,000	$27.01	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2	Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F3	25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.